Doctors told Monica Dudley-Weldon that her son might never walk or talk. One night, he unexpectedly said the words she had been waiting to hear: “I love you.”
When Beckett was diagnosed with a SYNGAP1-related disorder, he was one of only six identified patients Monica could find. Getting that answer required 19 specialists, a $13,000 genetic test, a 14-week wait, and the willingness to take a chance when success was far from guaranteed.
Monica refused to let the diagnosis become the end of Beckett’s story.
A former science teacher, she founded the first organization dedicated to advancing SYNGAP1 research, awareness, and family support. Her work helped establish a patient registry, natural history research, an ICD-10 code, and new collaborations among families, researchers, biotechnology companies, and policymakers.
That journey eventually led Monica into law, health policy, biotech strategy, and chemical and biological defense work with the federal government.
IN THIS EPISODE, YOU’LL LEARN:
- Why Monica borrowed $13,000 for a genetic test with only a 20% chance of finding an answer
- How Beckett became one of the earliest identified SYNGAP1 patients
- How one family helped create an international rare disease movement
- Why patient registries and natural history studies matter to drug development
- How patient priorities can differ from what researchers expect
- Why many rare disease nonprofits need more sustainable business models
- How patient data can responsibly support future research
- Why community conflict can drive away researchers and biotech companies
- How families can recognize unsupported treatments and questionable medical claims
- How rare disease advocacy prepared Monica for biotechnology and national defense
- What personal loss, faith, and starting again taught her about leadership
WHY THIS MATTERS:
Rare disease families often live with immediate challenges including seizures, behavioral symptoms, intellectual disability, and uncertainty while treatments can take years or even decades to develop.
Monica’s story demonstrates why patients and caregivers must have a meaningful voice in deciding what research addresses first. It also shows what can happen when lived experience is combined with science, business, law, policy, and persistent advocacy.
A diagnosis can describe a condition, but it does not have to define a child’s future.
CHAPTERS:
00:00 Doctors Said He Would Never Talk
01:31 Meet Monica Dudley-Weldon
03:05 From Patient Advocacy to National Defense
08:39 Nineteen Specialists and a $13,000 Decision
10:17 A Genetic Test With a 20% Chance
11:35 Beckett Becomes Patient Number Six
12:42 Building a SYNGAP1 Research Movement
15:55 Turning a 30-Year Timeline Into Eight
22:07 Why Pharmaceutical Funding Is Complicated
24:29 A New Model for Rare Disease Research
28:11 Why Rare Disease Data Is So Valuable
31:30 Hearing What Beckett Would “Never” Do
34:00 The First Time Beckett Said “I Love You”
37:02 Building Something That Can Survive
39:37 When Politics Blocks Medical Innovation
43:22 Identifying Charlatans and Unsupported Treatments
46:56 A Classroom Experiment Inspires Real Research
50:13 What Patients Need Before a Cure
53:08 What Monica Would Tell Her Younger Self
55:50 Choosing Triumph Over Tragedy
Subscribe to Building the Noise for more conversations about healthcare, biotechnology, patient advocacy, public policy, and the people working to improve broken systems.
Listen to the full episode, share it with a parent, caregiver, researcher, or advocate who needs to hear it, and leave a rating or review to support the show.
SYNGAP1, rare disease, rare disease advocacy, patient advocacy, genetic disorders, genetic testing, Monica Dudley-Weldon, SYNGAP1 research, patient-led research, special needs parenting, intellectual disability, epilepsy, biotechnology, healthcare policy, drug development, patient data, nonprofit leadership, medical research, national defense, Building the Noise
Support the show
Building the Noise with Matt Toresco
